内皮研究组:波生坦对 NAION 患者的影响 (ENDOTHELION)
波生坦对非动脉炎性缺血性视神经病变患者的影响
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years. The visual prognosis of the condition is unfavorable in the great majority of cases, with significant effects on the visual field and vision. The severity of the unilateral condition is also associated with bilateralization in 15% at 5 years. There is no effective treatment for the acute phase of the disease or to reduce the rate of bilateralization. In this context, it is essential to develop new therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve damage.
研究概览
详细说明
The main objective of our study will be to compare the treatment with bosentan to placebo for 8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional (visual acuity, visual field). The primary endpoint will be the improvement of the visual field, a major criterion of the affected visual function in this disease.
The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the effectiveness of drug treatment in the absence of continuous positive airway pressure (set up after three months if necessary, feasible confounding factor for the evaluation of results ), the period of three months is sufficient to assess the anatomical and functional recovery (disappearance of papilledema).
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Angers、法国、49100
- University Hospital of Angers
-
Bordeaux、法国、33000
- University Hospital of Bordeaux
-
Grenoble、法国、38043
- CHU de Grenoble
-
Grenoble、法国、38043
- University Hospital of Grenoble Michallon
-
Paris、法国、75019
- Ophtalmological fondation of Rothschild + Bichat Hospital
-
Saint-Etienne、法国、42055
- University hospital of Saint-Etienne
-
-
Paris
-
Paris、Paris、法国
- Centre National d'Ophtalmologie XV-XX
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Non arteritic ischemic optic neuropathy (NAION) with onset < 21 days
- Age ≥ 50 years old
- Signed informed consent form
- Patients affiliated with a national health insurance scheme or beneficiaries of such a scheme
Exclusion Criteria:
- Pregnant women, women in labour or breast-feeding mother
- Patients with other acute or chronic intercurrent ocular pathology interfering with visual acuity or visual field (diabetes, drug-induced or other retinopathy, other optic neuropathy including uni- or contralateral glaucoma and/or intraocular pressure > 30 mmHg, advanced cataract, corneal opacities, amblyopia < 5/10, severe myopia > -6 diopters, retinal disease)
- Simultaneous bilateral NAAION, 1 month apart or less
- Signs that may raise suspicion of other inflammatory neuropathy: arterial NAAION (Horton's disease), pain on eye movement or any signs suggestive of optic neuritis, known diagnosis of multiple sclerosis, history of inflammatory optic neuropathy (homo- or ipsi-lateral). A temporal artery biopsy should be performed if there are symptoms suggestive of Horton's disease, or if there is pale and/or diffuse edema, or obliteration of the associated central retinal artery.
- Patients with systolic blood pressure below 100 mmHg
- Patient with orthostatic hypotension (20 mmHg drop in SBP and/or 10 mmHg drop in DBP when moving to a standing position)
- Neurological history of vascular or tumour-related changes to the visual field or other optic neuropathy
- Systemic inflammatory disease
- Known allergy to bosentan
- Patients with moderate to severe hepatic impairment (Child-Pugh class B or C), biliary cirrhosis (serum levels of liver aminotransferases, aspartate aminotransferases (ASAT) and/or alanine aminotransferases (ALAT), greater than three times the upper limit of normal, bilirubin greater than twice normal)
- Estimated glomerular filtration rate (GFR) < 30 ml/min/1.73 m2
- Patients treated with drugs whose efficacy may be reduced by activation of cytochrome P450, 2C9, 3A4 and 2C19 isoenzymes
- Patients treated with amiodarone
- Patient treated with systemic corticosteroids (background treatment or treatment initiated at the time of NAAION diagnosis)
- Person deprived of liberty by judicial or administrative decision, adult protected by law, hospitalized person
- Ongoing participation in another clinical research study or in the exclusion period of another clinical study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Bosentan
Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks |
treatment by bosentan or placebo is randomized , 125 mg twice a day |
|
安慰剂比较:Placebo
placebo drug , twice a day, during eight weeks |
treatment by bosentan or placebo is randomized |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
mean deviation of automated visual field
大体时间:3 month
|
Humphrey 30-2 SITA-standard |
3 month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
visual acuity
大体时间:6, 12 and 24 month
|
ETDRS scale |
6, 12 and 24 month
|
|
optic nerve fiber layer thickness
大体时间:3, 6, 12 and 24 month
|
OCT measurement |
3, 6, 12 and 24 month
|
|
mean deviation of automated visual field for healthy eye and NAION eye
大体时间:3, 6, 12 and 24 month
|
Humphrey 30-2 |
3, 6, 12 and 24 month
|
|
inflammatory marker and prepro-endothelin dosing
大体时间:3 month
|
RANTES, MCP-1, TNF-α, INF-γ, IL-6, IL-10 and TGF-β |
3 month
|
|
mean deviation of automated visual field for controlateral eye
大体时间:24 month
|
Humphrey 30-2 sita-standard |
24 month
|
|
VFQ-25 score
大体时间:3 and 12 month
|
VFQ-25 quality of life |
3 and 12 month
|
|
rate of bilateral occurence of NAION
大体时间:at 24 month visit
|
rate of bilateralization |
at 24 month visit
|
合作者和调查者
调查人员
- 首席研究员:Christophe Pr CHIQUET, Prof, MD, PhD、University Hospital, Grenoble
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.